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Carcinomas of unknown primary site are metastatic malignant
epithelial tumours whose primary site cannot be identified during
pretreatment assessment. They are characterised by their slow
local development and their high metastatic potential. The primary
site remains unknown in 20–50% of the patients, but the results
from autopsies show that the primary tumours are most often
located in the pancreas, lung, gut or kidney.
In France, the incidence of carcinomas of unknown primary site
is eight out of 100000 per year, corresponding to between 5 and
7% of the solid tumours in adults. The average age at detection is
60 years old, with slightly more men being affected. The median
survival time is only a few months.
The heterogeneity of carcinoma of unknown primary site is due
to the different histopathological types and anatomical localisa-
tions, making this a difficult topic to cover. In this document, we
present the diagnostic strategy based on these two parameters,
with the first entry point being the histopathological type. The
therapeutic strategies to be used depend on the prognostic factors:
specific anatomoclinical entities (neuroendocrine tumours, cervi-
cal lymph node metastases from squamous cell carcinoma, axillary
lymph node metastases from an adenocarcinoma in women,
undifferentiated carcinoma of the mediastinum in young men) and
other nonspecific situations. Although primary papillary serous
carcinoma is no longer included in the classification of peritoneum
carcinomas of unknown primary site, we covered the management
in women here in an attempt to be exhaustive.
OBJECTIVES
The objective was to define guidelines for the management of adult
patients with carcinomas of unknown primary site. These guide-
lines are aimed at health professionals treating these patients with
the goal of helping to homogenising clinical practice.
The principal questions addressed in this document are:
  What pathological diagnostic strategies should be used for each
localisation?
  To what extent should the primary site be searched for, and
what are the limits for this strategy?
  What are the prognostic factors?
  What treatment strategies should be used for each anatomocli-
nical type?
METHODS
The details of the full methodology have been previously published
(Fervers et al, 2001). In summary, a multidisciplinary working
group was set up by the French National Federation of Cancer
Centres (Fe ´de ´ration Nationale des Centres de Lutte Contre le
Cancer–FNCLCC) to review the literature on the management of
patients with carcinomas of unknown primary site.
Medline
s was searched between 1980 and 2001 using keywords
pertinent for each topic covered and this was completed with
references provided by the members of the working group. The
majority of the articles were in English and French.
After selection and critical appraisal of this literature, the
working group defined the ‘Standards’, ‘Options’ and ‘Recommen-
dations’ (SORs) for the management of patients with carcinomas
of unknown primary site, based on a synthesis of the best available
evidence and expert agreement. These guidelines were then
reviewed by a group of independent experts (see the Appendix)
and finalised after taking into consideration their comments. SORs
are considered as being validated when the members of the
working group give their agreement for publication.
When all the members of the working group agree, based on the
best available evidence, that a procedure or intervention is
beneficial, inappropriate, or harmful, it is classified as a ‘Standard’,
and when the majority agree, it is classified as an ‘Option’ (Table 1).
In the SORs, there can be several ‘Options’ for a given clinical
situation. ‘Recommendations’ provide additional information
that enable the available options to be ranked using explicit
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www.bjcancer.comcriteria (e.g. survival, toxicity) with an indication of the level of
evidence. These recommendations thus help clinicians to select
an appropriate option. Thus, clinicians can make choices for
the management of patients using this information and taking into
consideration local circumstances, skills, equipment, resources
and/or patient preferences. The adaptation of the SOR to the
local situation is allowable if the reason for the choice is
sufficiently transparent and this is crucial for successful imple-
mentation. Inclusion of patients in clinical trials is an appro-
priate form of patient management in oncology and is recom-
mended frequently within the SORs, particularly in situations
where only weak evidence exists to support a procedure or an
intervention.
The type of evidence underlying any ‘Standard’, ‘Option’ or
‘Recommendation’ is indicated using a classification developed by
the FNCLCC based on previously published methods. The level of
evidence depends not only on the type and quality of the studies
reviewed, but also on the concordance of the results (Table 2).
When no clear scientific evidence exists, judgement is made
according to professional experience and consensus of the expert
group (‘expert agreement’), and this is then validated by the peer-
review process.
This is a translation of the French version of the summary
rapport (Bugat et al, 2002), which was based on the full-text
version in French, available on internet at the following address:
http://www.fnclcc.fr. The document will be updated as new
evidence becomes available or there is a change in expert
agreement.
The list of abbreviations used in this article and their meaning is
given in Table 3.
PATHOLOGICAL EXAMINATION
Treatment of samples prior to pathological examination
Samples should be fixed using buffered formalin or AFA (acetic
acid, formaldehyde, alcohol) (standard, level of evidence: B2). The
standard staining technique is haematoxylin and eosin (standard,
level of evidence: B2). Immunohistochemical investigations should
be performed using a panel of antibodies (standard, level of
evidence: B2). Samples can be frozen directly in liquid nitrogen
and then stored in a freezer at  801C or lower, or stored in liquid
nitrogen (option, expert agreement).
Strategies for specific histopathological types
(Figures 1–3)
Undifferentiated malignant tumour An immunohistochemical
investigation should be performed to eliminate the diagnosis of
lymphoma, melanoma or germ cell tumour. This should involve
the use of a panel of reference antibodies against epithelial
antigens (pan-cytokeratins), lymphoid antigens (CD45, CD20,
CD3), melanotic antigens (PS100 et HMB45) and germ cell tumour
antigens (aFP, bHCG, PLAP) depending on the clinical presenta-
tion (standard, level of evidence: B2).
Undifferentiated carcinoma or adenocarcinoma Neuroen-
docrine tumour markers should be used in the immunohisto-
chemical investigation (e.g. chromogranin, synaptophysin), as
well as carcinoma markers (cytokeratins: CK5/6, CK7, CK19,
CK20, ACE) and other antibodies depending on the anatomo-
clinical presentation (e.g. thyroglobulin, prostate specific
antigen (PSA), hormonal receptors) (standard, level of evidence:
B2).
Table 2 Definition of level of evidence
Level A
There exists a high-standard meta-analysis or several high-quality randomised
clinical trials that give consistent results
Level B
There exist good quality evidence from randomised trials (B1) or prospective or
retrospective studies (B2). The results are consistent when considered together
Level C
The methodology of the available studies is weak or their results are not consistent
when considered together
Level D
Either the scientific data do not exist or there is only a series of cases
Expert agreement
The data do not exist for the method concerned, but the experts are unanimous
in their judgement
Table 3 Abbreviations and their meanings
CK Cytokeratins KL1, CK5/6, CK7, CK19, CK20
CD45 Leucocyte differentiation antigens
PS 100 Protein S100
CD20 B lymphocyte
CD3 T lymphocyte
EMA Epithelial membrane antigen
CD30 Activation antigen
ALK Anaplastic lymphoma kinase
HMB45, melan A Melanic markers
SMA Smooth muscle actin
SMD Striated muscle desmin
CD31,CD34 Vascular ‘markers’
CD68 Histiocyte ‘marker’
CD99 Primitive neuroectodermal tumour (PNET) ‘marker’
CD117 c-kit protein
VIM Vimentin
Calretinin, HBME1, WT1 Mesothelial markers
PLAP Placental alkaline phosphatase
AFP a-Foetoprotein
bHCG b-Human chorionic gonadotrophin
CGA Chromogranin A
SYN Synaptophysin
NSE Neurone specific enolase
CEA Carcinoembryonic antigen
Hep Par1 Hepatocellular antigen
PSA Prostate specific antigen
TTF1 Thyroid transcription factor 1
GCDFP Gross cystic disease fluid protein
ER Oestrogen receptors
PR Progesterone receptors
GFAP Glial fibrillary acidic protein
NF Neurofilaments
Table 1 Definition of Standards, Options and Recommendations
Standards Procedures or treatments that are considered to be of
benefit inappropriate or harmful by unanimous decision,
based on the best available evidence
Options Procedures or treatments that are considered to be of
benefit, inappropriate or harmful by a majority, based on the
best available evidence
Recommendations Additional information to enable the available options to be
ranked using explicit criteria (e.g. survival, toxicity) with an
indication of the level of evidence
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An immunohistochemical investigation for the diagnosis should be
performed using an appropriate panel of specific antibodies
(standard). This should enable the diagnosis of lymphoma,
melanoma, germ cell tumour and sarcoma to be eliminated and
the diagnosis of prostate, breast, ovary, thyroid or neuroendocrine
tumours to be positively identified. A sample can be frozen to
enable typing, cytogenetic and, particularly, molecular biological
studies to be performed later (option). The clinician and
pathologist should compare their opinions before and after the
pathological diagnosis (recommendation, expert agreement).
DIAGNOSTIC STRATEGY
Systematic diagnostic assessment
Diagnostic strategy should aim to identify anatomoclinical entities
of carcinomas of unknown primary site for which there is a
specific treatment (standard, level of evidence: B2). For other
anatomoclinical entities, identification of the primary tumour has
no impact on the prognostic or therapeutic consequences, thus a
systematic complete assessment is unnecessary (standard, level of
evidence: B2). The systematic diagnostic assessment is sum-
marised in step 1 in Table 4.
Specific work-up to eliminate diagnosis of extragonadal
germ cell tumour
The main differential diagnoses for patients with carcinomas of
unknown primary site are extragonadal germ cell tumour and
lymphoma, because they are potentially curable. The specific
work-up for eliminating the diagnosis of extragonadal germ cell
tumour, includes a systematic diagnostic work-up and a specific
work-up for adenocarcinomas and undifferentiated carcinomas
(standard).
Diagnostic work-up depending on histopathological and
anatomic localisation (Figures 4–6)
The diagnostic steps (steps 2 and 3), performed depending on the
histopathological and anatomic localisation, are shown in Table 4.
Figures 2 and 3
Diagnostic step 1
Standards
•  Questions and history taking
•  Complete clinical examination
•  Lung X-ray
Diagnosis of carcinoma of
unknown primary site
Pathological examination
Tumour of unknown primary site
Figure 4 Figure 7 Figure 6
Histopathological type?
Adenocarcinoma and poorly
differentiated carcinoma
Neuroendocrine carcinoma  Squamous cell carcinoma 

  
Figure 1 First diagnostic step for carcinoma of unknown primary site.
Histopathological examination
Figure  3
Adenocarcinoma Undifferentiated malignant tumour: CK, CD45, PS100 Squamous cell carcinoma 
•  CK
•
•
•
•  CD45
•  PS100
+
+
+
•  CK
•  CD45
•  PS100
+
−
−
•  CK
•  CD45
•  PS100
−
+
−
•  CK
•  CD45
•  PS100
−
−
+
•  CK
•  CD45
•  PS100
−
−
−
Probable
artefact: recontrol
sample
• •
•
•
•
•
Probable lymphoma:
B and T lymphocyte
markers
Anaplastic large cell:
complete with EMA,
CD 30, ALK
Probable melanoma:
complete with
HMB45, melan A
Probable sarcoma:
complete with AML,
DES, CD31, CD34,
CD68, CD99, CD117 Liposarcoma
Nerve sheath
malignant tumours
Germ cell tumours
Embryonic carcinoma, yolk sac tumour,
choriocarcinoma complete with: PLAP,
FP, HCG
Malignant
mesothelioma:
complete with
calretinin, CK5/6
Synovialosarcoma
Epithelioid sarcoma
Undifferentiated carcinoma
Figure 3


Figure 2 Histopathological diagnosis for carcinoma of unknown primary site.
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UNKNOWN PRIMARY SITE
No prospective studies or meta-analyses for prognostic factors
have been published, but there are several retrospective studies
with coherent results, which suggest that the following are the best
prognostic factors: general good health status; women; lymph node
metastases; neuroendocrine or squamous cell carcinoma; and few
metastatic sites (level of evidence: B2). It is recommended to
include patients with carcinomas of unknown primary site in
good-quality studies assessing prognostic factors (recommenda-
tion).
TREATMENT STRATEGY
Treatment of specific anatomoclinical entities
Treatment of neuroendocrine carcinoma (Figure 7) The treat-
ment of metastases from a neuroendocrine carcinoma is not
modified by the identification of the primary site (expert
agreement). The management of patients with neuroendocrine
carcinoma of unknown primary site should take into consideration
the cellular differentiation (standard, expert agreement).
Poorly differentiated forms are considered to be chemosensitive
(level of evidence: C). The usual treatment is based on a
combination of a platinum salt and etoposide (level of evidence:
C). Although the results from clinical trials do not provide
evidence for efficacy in terms of increased survival, clinicians
should prescribe this treatment (standard, expert agreement).
There is no standard for the forms that are well differentiated.
The treatment decision should be based on a multidisciplinary
decision taking into consideration the patient’s symptoms and the
progression of the carcinoma, particularly for those with well-
differentiated forms (recommendation).
Treatment of cervical lymph node metastases in patients with
squamous cell carcinoma (Figure 8) Patients with cervical lymph
node metastases from squamous cell carcinoma should be offered
lymph node dissection and complementary radiotherapy (stan-
dard, level of evidence: C). If surgery is not possible, radiotherapy
should be performed (standard). Chemotherapy can be proposed
to patients with tumours that are not suitable for resection or
surgery (option).
Adenocarcinoma Undifferentiated carcinoma 
• • • •
•
•
•
•
•
•
•
•
•
•
•
•
•
Complete with: C7, CK19, CK20, CEA Complete with: CK5/6 Complete with: CGA, SYN
•  Clinical signs
•  CK7
•  CK20
−
−
•  Clinical signs
•  CK7
•  CK20
−
+
•  Clinical signs
•  CK7
•  CK20
+
−
•  Clinical signs
•  CK7
•  CK20
+
+
Epidermoid
carcinoma
Hepatocelluar carcinoma:
complete with FP, polyclonal
CEA, hepatocelluar antigen
Renal carcinoma:
complete with VIM
Prostate adenocarcinoma:
complete with PSA
Colorectal
adenocarcinoma:
CEA+
Broncho-pulmonary
adenocarcinoma: complete
with TTF1
Breast carcinoma (canalicular
and lobular): complete with
EMA, GCDFP, OR/PR
Nonmucinous ovarian
carcinoma: CA 125
Endometrial carcinoma
Thyroid carcinoma: complete
with thyroglobuline, TTF1
Cholangiocellular carcinoma:
CEA+, CK19+
Urothelial carcinoma
Pancreatic carcinoma:
CEA+
Biliary carcinoma: CEA+
Mucinous ovarian 
carcinoma
Gastric carcinoma: CEA+
Neuroendocrine carcinoma
Thyroid medullar carcinoma:
complete with thyrocalcitonin,
CEA
Merkel cell carcinoma:
complete with CK20 and NF
Figure 3 Histopathological diagnosis of undifferentiated carcinoma and adenocarcinoma.
Adenocarcinoma and
undifferentiated carcinoma 
 FP
 HCG
•
•
•
•
•
PSA
Diagnostic step 2
Standards for men
Standards for women
Mammography
Ultrasound or pelvic CT scan
Localisation?
Figure 5 
Figure 4 Second diagnostic step for adenocarcinoma and undifferen-
tiated carcinoma.
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Step 1 Step 2 Step 3
Routine diagnostic
work-up
Specific work-up
depending on the
histopathology
Specific work-up as a function of localisation
Localisation Standards Options Recommendations
Neuroendocrine
carcinoma
There are no standards There are no options There are no
recommendations
Carcinoma of unknown
primary site
Adenocarcinoma and
undifferentiated
carcinoma
Midline adenopathies Testicular ultrasound (level of
evidence: B2)
Chest-abdominal CT scan
(level of evidence: B2)
There are no options There are no
recommendations
Standards
Pathological evaluation
(level of evidence: B2)
Clinical history (level of
(Standards, level of evidence:
B2):
Mediastinal adenopathies Testicular ultrasound and
chest-abdominal CT scan to
eliminate a germ cell tumour
in men
There are no options There are no
recommendations
evidence: B2)
Clinical examination (level
of evidence: B2)
Chest X-ray (level of
evidence: B2)
No complete work-up
(level of evidence: B2)
For women
Mammography
Ultrasound or pelvic CT
scan
For men
Serum PSA, aFP, bHCG
assays
Cervical and/or supraclavicular
adenopathies
Testicular ultrasound (in the
presence of an associated
midline adenopathy)
Chest-abdominal CT scan
There are no options Panendoscopy and neck and
face CT scan, serology for
Epstein–Barr virus or
detection of DNA by in situ
hybridisation to eliminate
diagnosis of an
undifferentiated
nasopharyngeal carcinoma
(expert agreement)
Axillary adenopathy (women) Breast ultrasound
a (level of
evidence: C)
There are no options There are no
recommendations
Breast MRI
a (level of evidence:
C)
Inguinal adenopathy There are no standards There are no options There are no
recommendations
Liver metastases Woman: aFP assay if
undifferentiated carcinoma
Coloscopy Coloscopy in the presence
exclusive, resectable liver
metastases (expert
agreement)
Lung metastases Women: bHCG assay
Men: chest-abdominal CT scan
and testicular ultrasound
There are no options There are no
recommendations
Bone metastases There are no standards There are no options Bone scintigraphy and
standard X-rays of painful
zones
Brain metastases There are no standards There are no options There are no
recommendations
Single metastasis There are no standards Whole-body CT scan (expert
agreement)
Bone scintigraphy
There are no
recommendations
Pleural effusion There are no standards Chest CT scan (expert
agreement)
There are no
recommendations
Peritoneal effusion
b There are no standards Abdominal-pelvic CT scan in
women
There are no
recommendations
Squamous cell carcinoma
No specific work-up for this
histopathological type
Cervical adenopathy Panendoscopy (level of
evidence: B2)
There are no options There are no
recommendations
Head and neck CT scan (level
of evidence: B2)
Diagnostic bilateral
amygdalectomy
Supraclavicular or axillary
adenopathy
There are no standards Chest CT scan There are no
recommendations
Inguinal
adenopathy
Clinical examination of the
external genital organs
Pelvic CT scan or ultrasound There are no
recommendations
Anuscopy and colposcopy
Bone metastases Complete clinical examination
with a head and neck
examination (expert
agreement)
Panendoscopy Bone scintigraphy and
standard X-rays of painful
zones (expert agreement)
aExamination to be performed after a ‘negative’ mammography.
bAlthough this entity is not included in the classification of ‘carcinoma of unknown primary site’ because the primary
tumour is known, the therapeutic implications from its diagnosis lead the working group to include this entity in the current SOR document. CT¼computed tomography;
PSA¼prostate antigen specific; aFP¼a-foetoprotein; bHCG¼b-human chorionic gonadotrophin; MRI¼magnetic resonance imaging.
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Mediastinal, cervical,
supraclavicular adenopathy
Axillary adenopathy
Inguinal adenopathy
Liver metastases
Lung metastases
Bone metastases
Brain metastases
Unique metastasis
Localisation?
Pleural effusion
Peritoneal effusion
Diagnostic step 3
Standards
•
•
•
•
Testicular ultrasound
Thoracic−abdominal CT scan
and
testicular ultrasound (men)
Thoracic − abdominal CT scan
Diagnostic step 3
Standards
Testicular ultrasounda
Thoracic−abdominal CT scan
•
•
Diagnostic step 3
Standards
Diagnostic step 3
Standards (women)
Diagnostic step 3
Standards
Diagnostic step 3
Options
Diagnostic step 3
Option
Diagnostic step 3
Options (women)
•
•
•
•
Breast ultrasoundb
Breast MRIb
Figure 9
Figure 9
Figures 8 and 10
Figure 10
Figure 10
Figure 10
Figure 10
Figure 10
Figure 10
Figure 10
Figure 10
FP assay in the presence of
an undifferentiated tumour
 HCG assay (women)
Options
Coloscopy
Whole−body CT scan
Chest CT scan
Abdominal−pelvic CT scan
Bone scintigraphy
aIn patients with brain and/or supraclavicular adenopathies,
testicular ultrasound should only be performed in those
with associated midline adenopathy.
bExamination to be performed if mammography is negative.











Figure 5 Third diagnostic step for adenocarcinoma and undifferentiated carcinoma.
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adenocarcinoma (Figure 9)
Locoregional treatment (breast): If the results from the breast
MRI are negative, surgery and breast radiotherapy should not be
offered (standard, expert agreement).
Locoregional treatment (axilla): Axillary dissection should be
offered (standard, expert agreement). Axillary and/or supraclavi-
cular irradiation can be undertaken (option, expert agreement).
Systemic treatment: The management of these patients should be
identical to that for patients with breast cancer with lymph node
metastases (recommendation).
Treatment of primary papillary serous carcinoma in women By
analogy with ovarian cancer, the standard treatment is tumour
reduction by surgery (level of evidence: D) followed by poly-
chemotherapy containing a platinum salt (standard, expert
agreement). About six cycles of treatment should be undertaken
(recommendation).
Treatment for carcinomas of unknown primary site not belonging
to a specific anatomoclinical entity (Figure 10)
Locoregional treatment: Patients with a single metastatic site can
be offered specific treatment (option, expert agreement).
Systemic treatment: Several treatments can be envisaged (op-
tions): chemotherapy (level of evidence: B2), symptomatic
Squamous cell carcinoma 
Cervical
adenopathy
Inguinal
adenopathy
Supraclavicular or axillary
adenopathy
Bone
metastases
•
•
Diagnostic step 3
Standard
Diagnostic step 3
Standards Diagnostic step 3
Standards
Diagnostic step 3
Option Head and neck examination
Option:
Panendoscopy
•
•
•
Clinical examination of the
external genital organs
Anuscopy
Colposcopy
Chest CT scan
Head and neck panendoscopy
Cranial−cervical−facial CT scan
Figure 10
Figure 10
Figure 10 Figure 8
Yes No
Not covered in this SOR
Anuscopy and/or
colposcopy positive ?
•
•
 


Figure 6 Complementary examinations for squamous cell carcinoma.
Yes No
Neuroendocrine carcinoma
Well−differentiated
tumour?
Standard Standard
There is no standard Chemotherapy−association of platinum − etoposide
Figure 7 Treatment of neuroendocrine carcinoma.
Metastatic cervical adenopathy
Resectable tumour? Yes No
Stage N1, N2a Stage N2b, N2c, N3
Standard Standards
Radiotherapy
Chemotherapy
Complementary radiotherapy
Option
Lymph node surgery •
•
Figure 8 Treatment of cervical lymph node metastases in patients with
squamous cell carcinoma.
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patients with bone metastases. If chemotherapy is prescribed, it is
recommended to administer a combination therapy with two
drugs, containing cisplatin (recommendation, expert agreement)
for patients with a good general health status (WHO performance
status of 1 or less). The treatment response should be evaluated
early (after two cycles) to avoid treatment in patients with known
progressive disease (recommendation).
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Axillary adenopathy
Woman?
Systemic treatment
Treatment similar to that for breast cancer
with lymph node metastases
Axillary and/or supraclavicular irradiation
Option
Standard
Axillary dissection
Locoregional treatment
If the mammary MRI is negative, surgery
and radiotherapy are not recommended
Undifferentiated tumour?
 Figures 10
Adenocarcinoma
Option
Chemotherapy
Yes No
Figure 9 Treatment of axillary lymph node metastases in patients with
adenocarcinoma.
General treatment for carcinoma of unknown primary site not
belonging to a specific anatomoclinical entity
Liver metastases Other localisation Lung metastases
Elevated FP? Elevated HCG?
Systemic treatment
Standard
Options
Option
Local treatment
There is no standard
•  Chemotherapy
•  Symptomatic treatment only
•  Biphosphonates for patients with bone metastases
Specific treatment in patients with a unique
metastasis
Not covered
in this SOR
Not covered
in this SOR
Yes Yes No No
Figure 10 General treatment of carcinoma of unknown primary site not
belonging to a specific anatomoclinical entity.
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